Suberoylanilide hydroxamic acid (vorinostat) post chemotherapy in hormone refractory prostate cancer (HRPC) patients (pts): A phase II trial by the Prostate Cancer Clinical Trials Consortium (NCI 6862) Meeting Abstract

  

Authors:	Hussain, M.; Dunn, R.; Rathkopf, D.; Stadler, W.; Wilding, G.; Smith, D. C.; Bradley, D.; Cooney, K. A.; Zweibel, J.; Scher, H.
Abstract Title:	Suberoylanilide hydroxamic acid (vorinostat) post chemotherapy in hormone refractory prostate cancer (HRPC) patients (pts): A phase II trial by the Prostate Cancer Clinical Trials Consortium (NCI 6862)
Meeting Title:	43rd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	25
Issue:	18 Suppl.
Meeting Dates:	2007 Jun 1-5
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2007-06-20
Start Page:	267s
Language:	English
ACCESSION:	WOS:000455043701259
PROVIDER:	wos
DOI:	10.1200/jco.2007.25.18_suppl.5132
Notes:	Meeting Abstract: 5132 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/141632